Results 61 to 70 of about 10,433 (192)

Development of a physiologically based kinetic model for 99m-Technetium-labelled carbon nanoparticles inhaled by humans [PDF]

, 2009
International audienceParticulate air pollution is associated with respiratory and cardiovascular morbidity and mortality. Recent studies investigated whether and to which extent inhaled ultrafine particles are able to translocate into the bloodstream in
Bois, Frédéric Y., Brochot, Céline, Hoet, Peter, Nemmar, Abderrahim, Pery, Alexandre R.R.   +4 more
core   +2 more sources

Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity

Clinical Pharmacology &Therapeutics, EarlyView.
Cystic fibrosis (CF) is a chronic hereditary disease that affects tens of thousands of people worldwide. The introduction of CFTR modulator therapies such as elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved the quality of life of people with CF.
Alan Shi, Cole Cornwell, Kyunghee Yang, Paul M. Beringer   +3 more
wiley   +1 more source

Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases

Scientific Reports, 2021
The advancement in the processing speeds of computing machines has facilitated the development of complex physiologically based pharmacokinetic (PBPK) models.
Muhammad F. Rasool, Shazia Ali, Sundus Khalid, Ramsha Khalid, Abdul Majeed, Imran Imran, Hamid Saeed, Muhammad Usman, Mohsin Ali, Amer S. Alali, Abdullah F. AlAsmari, Nemat Ali, Ali Mohammed Asiri, Fawaz Alasmari, Faleh Alqahtani   +14 more
doaj   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel, Filippa Schreeck, Simon Jaeger, Severin Schricker, Elke Schaeffeler, Svitlana Igel, Daniela Steinberger, Manuel Pagitz, Jörg Latus, Markus Ketteler, Kerstin Bühl, Marc‐H. Dahlke, Hans‐Georg Kopp, Matthias Schwab   +13 more
wiley   +1 more source

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

Pharmaceutics, 2020
Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure.
Tobias Kanacher, Andreas Lindauer, Enrica Mezzalana, Ingrid Michon, Celine Veau, Jose David Gómez Mantilla, Valerie Nock, Angèle Fleury   +7 more
doaj   +1 more source

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions

CPT: Pharmacometrics & Systems Pharmacology, 2021
The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a
Sebastian Frechen, Juri Solodenko, Thomas Wendl, André Dallmann, Ibrahim Ince, Thorsten Lehr, Jörg Lippert, Rolf Burghaus   +7 more
doaj   +1 more source

Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms [PDF]

, 2012
Physiologically based Pharmacokinetic (PBPK) models are used for predictions of internal or target dose from environmental and pharmacologic chemical exposures.
Jane C. Caldwell, Kannan Krishnan, Marina V. Evans   +2 more
core   +1 more source

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Clinical Pharmacology &Therapeutics, EarlyView.
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Janne T. Backman
wiley   +1 more source

Comparing computational times for simulations when using PBPK model template and stand-alone implementations of PBPK models

Frontiers in Toxicology
IntroductionWe previously developed a PBPK model template that consists of a single model “superstructure” with equations and logic found in many physiologically based pharmacokinetic (PBPK) models.
Amanda S. Bernstein, Amanda S. Bernstein, Paul M. Schlosser, Dustin F. Kapraun   +3 more
doaj   +1 more source